Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has been assigned a consensus recommendation of “Moderate Buy” from the eighteen analysts that are presently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $65.41.

APLS has been the topic of a number of research reports. Robert W. Baird dropped their target price on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating on the stock in a report on Monday, September 23rd. Wedbush boosted their target price on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. Mizuho dropped their target price on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a report on Thursday, October 24th. Scotiabank started coverage on shares of Apellis Pharmaceuticals in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $35.00 target price on the stock. Finally, HC Wainwright dropped their target price on shares of Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, August 2nd.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the completion of the sale, the director now directly owns 100,000 shares in the company, valued at approximately $3,623,000. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 6.80% of the company’s stock.

Institutional Trading of Apellis Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of APLS. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Apellis Pharmaceuticals in the first quarter worth $89,000. nVerses Capital LLC lifted its stake in shares of Apellis Pharmaceuticals by 300.0% in the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock worth $107,000 after buying an additional 2,100 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after buying an additional 781 shares during the last quarter. CWM LLC lifted its stake in shares of Apellis Pharmaceuticals by 299.9% in the second quarter. CWM LLC now owns 4,151 shares of the company’s stock worth $159,000 after buying an additional 3,113 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Apellis Pharmaceuticals by 1,300.8% in the first quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company’s stock worth $211,000 after buying an additional 3,330 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Trading Down 1.6 %

Shares of NASDAQ:APLS opened at $27.26 on Friday. The company has a market cap of $3.31 billion, a PE ratio of -7.88 and a beta of 0.87. The company’s 50-day moving average price is $32.52 and its 200 day moving average price is $37.94. Apellis Pharmaceuticals has a fifty-two week low of $26.28 and a fifty-two week high of $73.80. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The company had revenue of $199.70 million for the quarter, compared to the consensus estimate of $190.89 million. During the same period in the previous year, the firm earned ($1.02) EPS. Apellis Pharmaceuticals’s revenue was up 110.2% on a year-over-year basis. Sell-side analysts anticipate that Apellis Pharmaceuticals will post -1.37 earnings per share for the current year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).